Analyst consensus rating
Biogen Analyst Rating: Buy
Direct answer
Biogen's consensus rating is Buy.
31 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $236.87.
Forecast evidence checked September 9, 2026.
Get free Biogen email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $212.50
- Average price target
- $236.87
- High price target
- $300.00
- Low price target
- $165.00
- Low target gap
- -22.4%
- Target upside
- +11.5%
- High target gap
- +41.2%
- Target range width
- 63.5%
- Consensus rating
- Buy
- Analysts
- 31
- Evidence date
- September 9, 2026
- Valid through
- September 16, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Biogen?
Biogen has a verified Buy consensus. The same dataset has an average price target of $236.87.
How far are Biogen's low and high targets from the recorded price?
The low target implies -22.4%, while the high target implies +41.2%.
How many analysts are included in Biogen's consensus?
The verified consensus includes 31 analysts.
How is Biogen's target upside or downside calculated?
The average target of $236.87 is divided by the recorded price of $212.50, then one is subtracted to produce +11.5%. This does not guarantee a future return.
When was Biogen's analyst forecast verified?
The data was verified on 2026-09-09. The dataset is valid through 2026-09-16.